Current Neuro-Oncology
Volume
21 Number 2
28 February 2019
Home > Publications > Current Neuro-Oncology > Volume 21, Year 2019 > Number 2, 28 February
Mistry AM.
On
the subventricular zone origin of human glioblastoma.
Transl
Cancer Res. 2019 Feb;8(1):11-13∟.
doi: 10.21037/tcr.2018.11.31∟.
PMID: 30873355∟.
Comment. ˍ
Refers
to:
Lee
JH, et al.,
Human
glioblastoma arises from subventricular zone cells with low-level
driver mutations.
Nature.
2018 Aug 1. 2018;560(7717):243-247∟.
doi:: 10.1038/s41586-018-0389-3∟.
PMID: 30069053∟.
Laboratory investigation.
ˍ
Perez-Somarriba M, Andión M, López-Pino MA, Lavarino
C, Madero L, Lassaletta A.
Old
drugs still work! Oral etoposide in a relapsed
medulloblastoma.
Childs Nerv Syst. 2019 Feb
1;35(5):865-869∟.
doi: 10.1007/s00381-019-04072-9∟.
PMID: 30707305∟.
Case report. ˍ
Nilsson J, Järås J, Henriksson R, Holgersson G,
Bergström S, Estenberg J, Augustsson T, Bergqvist M.
No
Evidence for Increased Brain Tumour Incidence in the Swedish
National Cancer Register Between Years 1980-2012.
Anticancer
Res. 2019 Feb 2;39(2):791-796∟.
doi: 10.21873/anticanres.13176∟.
PMID: 30711958∟.
Observational study. ˍ
Kim JY, Jackman JG, Woodring S, McSherry F, Herndon JE, Desjardins
A, Friedman HS, Peters KB.
Second
primary cancers in long-term survivors of glioblastoma.
Neurooncol
Pract. 2019 Feb 4;6(5):386-391∟.
doi: 10.1093/nop/npz001∟.
PMID: 31555453∟.
Observational study.
ˍ
Rodríguez-Lozano DC, Piña-Medina AG, Hansberg-Pastor
V, Bello-Alvarez C, Camacho-Arroyo I.
Testosterone
Promotes Glioblastoma Cell Proliferation, Migration, and Invasion
Through Androgen Receptor Activation.
Front
Endocrinol (Lausanne). 2019 Feb 4;10:1∟.
doi: 10.3389/fendo.2019.00016∟.
PMID: 30778332∟.
Laboratory investigation. ˍ
Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S,
McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE,
Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn
JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert
MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee
EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang
SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA,
Yung WKA, Ligon KL.
Buparlisib
in Patients With Recurrent Glioblastoma Harboring
Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label,
Multicenter, Multi-Arm, Phase II Trial.
J Clin
Oncol. 2019 Feb 4;37(9):741-750∟.
doi: 10.1200/JCO.18.01207∟.
PMID: 30715997∟.
Interventional study. ˍ
Akgül S, Patch AM, D'Souza RCJ, Mukhopadhyay P, Nones K,
Kempe S, Kazakoff SH, Jeffree RL, Stringer BW, Pearson JV, Waddell
N, Day BW.
Intratumoural
Heterogeneity Underlies Distinct Therapy Responses and Treatment
Resistance in Glioblastoma.
Cancers (Basel).
2019 Feb 6;11(2):190∟.
doi: 10.3390/cancers11020190∟.
PMID: 30736342∟.
Laboratory investigation. ˍ
Silvani A, De Simone I, Fregoni V, Biagioli E, Marchioni E, Caroli
M, Salmaggi A, Pace A, Torri V, Gaviani P, Quaquarini E, Simonetti
G, Rulli E, D'Incalci M; Italian Association of Neuro-Oncology.
Multicenter,
single arm, phase II trial on the efficacy of ortataxel in
recurrent glioblastoma.
J Neurooncol. 2019 Feb
6;142(3):455-462∟.
doi: 10.1007/s11060-019-03116-z∟.
PMID: 30726533∟.
Interventional study. ˍ
Ludmir EB, Mahajan A, Paulino AC, Jones JY, Ketonen LM, Su JM,
Grosshans DR, McAleer MF, McGovern SL, Lassen-Ramshad YA, Adesina
AM, Dauser RC, Weinberg JS, Chintagumpala MM.
Increased
Risk of Pseudoprogression among Pediatric Low-Grade Glioma
Patients Treated with Proton versus Photon Radiotherapy.
Neuro
Oncol. 2019 Feb 7;21(5):686-695∟.
doi: 10.1093/neuonc/noz042∟.
PMID: 30753704∟.
Observational study. ˍ
Murphy M, Dowling A, Thien C, Priest E, Morgan Murray D, Kesari S.
A
feasibility study of the Nativis Voyager®
device
in patients with recurrent glioblastoma in Australia.
CNS
Oncol. 2019 Feb 7;8(1):CNS31∟.
doi: 10.2217/cns-2018-0017∟.
PMID: 30727742∟.
Interventional study. ˍ
Salloum R, Chen Y, Yasui Y, Packer R, Leisenring W, Wells E, King
A, Howell R, Gibson TM, Krull KR, Robison LL, Oeffinger KC,
Fouladi M, Armstrong GT.
Late
Morbidity and Mortality Among Medulloblastoma Survivors Diagnosed
Across Three Decades: A Report From the Childhood Cancer Survivor
Study.
J Clin Oncol. 2019 Feb 7;37(9):731-740∟.
doi: 10.1200/JCO.18.00969∟.
PMID: 30730781∟.
Observational
study. ˍ
Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson
TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES,
Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ,
Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL,
Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen
PY, Prins RM.
Neoadjuvant
anti-PD-1 immunotherapy promotes a survival benefit with
intratumoral and systemic immune responses in recurrent
glioblastoma.
Nat Med. 2019 Feb
11;25(3):477-486∟.
doi: 10.1038/s41591-018-0337-7∟.
PMID: 30742122∟.
Interventional study. ˍ
Schalper KA, Rodriguez-Ruiz ME, Diez-Valle R, López-Janeiro
A, Porciuncula A, Idoate MA, Inogés S, de Andrea C,
López-Diaz de Cerio A, Tejada S, Berraondo P,
Villarroel-Espindola F, Choi J, Gúrpide A, Giraldez M,
Goicoechea I, Gallego Perez-Larraya J, Sanmamed MF, Perez-Gracia
JL, Melero I.
Neoadjuvant
nivolumab modifies the tumor immune microenvironment in resectable
glioblastoma.
Nat Med. 2019 Feb
11;25(3):470-476∟.
doi: 10.1038/s41591-018-0339-5∟.
PMID: 30742120∟.
Interventional study. ˍ
Zhao J, Chen AX, Gartrell RD, Silverman AM, Aparicio L, Chu T,
Bordbar D, Shan D, Samanamud J, Mahajan A, Filip I, Orenbuch R,
Goetz M, Yamaguchi JT, Cloney M, Horbinski C, Lukas RV, Raizer J,
Rae AI, Yuan J, Canoll P, Bruce JN, Saenger YM, Sims P, Iwamoto
FM, Sonabend AM, Rabadan R.
Immune
and genomic correlates of response to anti-PD-1 immunotherapy in
glioblastoma.
Nat Med. 2019 Feb
11;25(3):462-469∟.
doi: 10.1038/s41591-019-0349-y∟.
PMID: 30742119∟.
Laboratory investigation. ˍ
Migliorini D, Dutoit V, Allard M, Hallez NG, Marinari E, Widmer V,
Philippin G, Corlazzoli F, Gustave R, Kreutzfeldt M, Blazek N,
Wasem J, Hottinger A, Koka A, Momjian S, Lobrinus A, Merkler D,
Vargas MI, Walker PR, Patrikidou A, Dietrich PY.
Phase
I/II trial testing safety and immunogenicity of the multipeptide
IMA950/poly-ICLC vaccine in newly diagnosed adult malignant
astrocytoma patients.
Neuro
Oncol. 2019 Feb 12;21(7):923-933∟.
doi: 10.1093/neuonc/noz040∟.
PMID: 30753611∟.
Interventional study. ˍ
Huang J, Chaudhary R, Cohen AL, Fink K, Goldlust S, Boockvar J,
Chinnaiyan P, Wan L, Marcus S, Campian JL.
A
multicenter phase II study of temozolomide plus disulfiram and
copper for recurrent temozolomide-resistant glioblastoma.
J
Neurooncol. 2019 Feb 15;142(3):537-544∟.
doi: 10.1007/s11060-019-03125-y∟.
PMID: 30771200∟.
Interventional study. ˍ
Perez A, Merlini L, El-Ayadi M, Korff C, Ansari M, von Bueren AO.
Comment
on: Ketogenic diet treatment in recurrent diffuse intrinsic
pontine glioma in children: A safety and feasibility
study.
Pediatr Blood Cancer. 2019 Feb
15;66(7):e27664∟.
doi: 10.1002/pbc.27664∟.
PMID: 30767367∟.
Comment. ˍ
Refers
to:
van
der Louw EJTM, et al., Ketogenic diet treatment in recurrent
diffuse intrinsic pontine glioma in children: A safety and
feasibility study.
Pediatr
Blood Cancer. 2018 Nov 28, 2019:e27561∟.
doi:
10.1002/pbc.27561∟.
PMID:
30484948∟.
Observational
study.
ˍ
Herrlinger U, Tzaridis T, Mack F, Steinbach JP, Schlegel U, Sabel
M, Hau P, Kortmann RD, Krex D, Grauer O, Goldbrunner R, Schnell O,
Bähr O, Uhl M, Seidel C, Tabatabai G, Kowalski T, Ringel F,
Schmidt-Graf F, Suchorska B, Brehmer S, Weyerbrock A, Renovanz M,
Bullinger L, Galldiks N, Vajkoczy P, Misch M, Vatter H, Stuplich
M, Schäfer N, Kebir S, Weller J, Schaub C, Stummer W, Tonn
JC, Simon M, Keil VC, Nelles M, Urbach H, Coenen M, Wick W, Weller
M, Fimmers R, Schmid M, Hattingen E, Pietsch T, Coch C, Glas M;
Neurooncology Working Group of the German Cancer Society.
Lomustine-temozolomide
combination therapy versus standard temozolomide therapy in
patients with newly diagnosed glioblastoma with methylated MGMT
promoter (CeTeG/NOA-09): a randomised, open-label, phase 3
trial.
Lancet.
2019 Feb 16;393(10172):678-688∟.
doi: 10.1016/S0140-6736(18)31791-4∟.
PMID:
30782343∟.
Interventional
study. ˍ
Stupp R, Lukas RV, Hegi ME.
Improving
survival in molecularly selected glioblastoma.
Lancet.
2019 Feb 16;393(10172):615-617∟.
doi: 10.1016/S0140-6736(18)33211-2∟.
PMID: 30782332∟.
Comment. ˍ
Refers
to:
Herrlinger
U, et al., Lomustine-temozolomide combination therapy versus
standard temozolomide therapy in patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CeTeG/NOA-09): a
randomised, open-label, phase 3 trial.
Lancet.
2019 Feb 16;393(10172):678-688∟.
doi:
10.1016/S0140-6736(18)31791-4∟.
PMID:
30782343∟.
Interventional
study.
ˍ
Wang T, Long Q, Gao T.
Letter:
Thalamic Glioblastoma: Clinical Presentation, Management
Strategies, and Outcomes.
Neurosurgery. 2019
Feb 16;84(5):E288∟.
doi: 10.1093/neuros/nyz009∟.
PMID: 30770537∟.
Comment. ˍ
Refers
to:
Esquenazi
Y, et al., Thalamic Glioblastoma: Clinical Presentation,
Management Strategies, and Outcomes.
Neurosurgery.
2018 Jul 1, 2018;83(1):76-85∟.
doi:
10.1093/neuros/nyx349∟.
PMID:
28973417∟.
Observational
study.
ˍ
Franceschi E, Tosoni A, De Biase D, Lamberti G, Danieli D,
Pizzolitto S, Zunarelli E, Visani M, Di Oto E, Mura A, Minichillo
S, Scafati C, Asioli S, Paccapelo A, Bartolini S, Brandes AA.
Postsurgical
Approaches in Low-Grade Oligodendroglioma: Is Chemotherapy Alone
Still an Option?
Oncologist. 2019 Feb
18;24(5):664-670∟.
doi: 10.1634/theoncologist.2018-0549∟.
PMID: 30777895∟.
Observational study. ˍ
Kamran SC, Dworkin M, Niemierko A, Bussiere M, Oh KS, Loeffler JS,
Shih HA.
Patterns
of failure among low-grade glioma patients treated with proton
radiotherapy.
Pract Radiat Oncol. 2019 Feb
18;9(4):e356-e361∟.
doi: 10.1016/j.prro.2019.02.002∟.
PMID: 30790717∟.
Observational study. ˍ
De Barros A, Attal J, Roques M, Nicolau J, Sol JC,
Cohen-Jonathan-Moyal E, Roux FE.
Impact
on survival of early tumor growth between surgery and radiotherapy
in patients with de novo glioblastoma.
J
Neurooncol. 2019 Feb 19;142(3):489-497∟.
doi: 10.1007/s11060-019-03120-3∟.
PMID: 30783874∟.
Observational study. ˍ
Kikuchi R, Ueda R, Saito K, Shibao S, Nagashima H, Tamura R,
Morimoto Y, Sasaki H, Noji S, Kawakami Y, Yoshida K, Toda M.
A
Pilot Study of Vaccine Therapy with Multiple Glioma
Oncoantigen/Glioma Angiogenesis-Associated Antigen Peptides for
Patients with Recurrent/Progressive High-Grade Glioma.
J
Clin Med. 2019 Feb 20;8(2):263∟.
doi: 10.3390/jcm8020263∟.
PMID: 30791546∟.
Interventional
study.
ˍ
Al-Holou
WN, Hodges TR, Everson RG, Freeman J, Zhou S, Suki D, Rao G,
Ferguson SD, Heimberger AB, McCutcheon IE, Prabhu SS, Lang FF,
Weinberg JS, Wildrick DM, Sawaya R.
Perilesional
Resection of Glioblastoma Is Independently Associated With
Improved Outcomes.
Neurosurgery.
2019
Feb 25, 2020;86(1):112-121∟.
doi: 10.1093/neuros/nyz008∟.
PMID:
30799490∟.
Observational
study.
ˍ
Przystal JM, Waramit S, Pranjol MZI, Yan W, Chu G, Chongchai A,
Samarth G, Olaciregui NG, Tabatabai G, Carcaboso AM, Aboagye EO,
Suwan K, Hajitou A.
Efficacy
of systemic temozolomide-activated phage-targeted gene therapy in
human glioblastoma.
EMBO Mol Med. 2019 Feb
26;11(4):e8492∟.
doi: 10.15252/emmm.201708492∟.
PMID: 30808679∟.
Laboratory investigation. ˍ
Fang
X, Kong W, Yu Z, Qiu J, Duan H.
Letter
to the Editor Regarding "Can Early Postoperative
O-(2-18FFluoroethyl)-l-Tyrosine
Positron Emission Tomography After Resection of Glioblastoma
Predict the Location of Later Tumor Recurrence?"
World
Neurosurg. 2019 Feb 26;123:469∟.
doi: 10.1016/j.wneu.2018.10.050∟.
PMID:
30832182∟.
Comment.
ˍ
Refers
to:
Buchmann
N et al., Can Early Postoperative O-(2-18FFluoroethyl)-l-Tyrosine
Positron Emission Tomography After Resection of Glioblastoma
Predict the Location of Later Tumor Recurrence?
World
Neurosurg. 2018 Sep 27;121:e467-e474∟.
doi:
10.1016/j.wneu.2018.09.139∟.
PMID:
30267942∟.
Observational
study.
ˍ
Mahzouni P, Shavakhi M.
Prostate-Specific
Membrane Antigen Expression in Neovasculature of Glioblastoma
Multiforme.
Adv Biomed Res. 2019 Feb 27;8:18∟.
doi: 10.4103/abr.abr_209_18∟.
PMID: 30993088∟.
Laboratory investigation. ˍ
Bhalerao
S, Nagarkar R, Adhav A.
A
case report of high-grade astroblastoma in a young adult.
CNS
Oncol. 2019 Feb 28;8(1):CNS29∟.
doi: 10.2217/cns-2018-0012∟.
PMID:
30813777∟.
Case
report.
ˍ
Kebir
S, Rauschenbach L, Radbruch A, Lazaridis L, Schmidt T, Stoppek AK,
Pierscianek D, Stuschke M, Forsting M, Sure U, Keyvani K,
Kleinschnitz C, Scheffler B, Glas M.
Regorafenib
in patients with recurrent high-grade astrocytoma.
J
Cancer Res Clin Oncol. 2019 Feb 28;145(4):1037-1042∟.
doi: 10.1007/s00432-019-02868-5∟.
PMID:
30820715∟.
Observational
study.
ˍ
Raman
R, Raman A.
A
pituitary tumor turned-to-be a glioma: A surgical case from the
Madras General Hospital 1928.
Indian
J Cancer. 2019 Feb 28, 2018;55(4):424-427∟.
doi: 10.4103/ijc.IJC_12_19∟.
PMID:
30829288∟.
Case
report.
ˍ
Rodriguez J, Dionne K, Wu GF, Goyal MS, Bucelli RC.
Primary
Spinal Cord Glioblastoma Multiforme in the Young and
Old.
Neurohospitalist. 2019 Feb
28;9(4):243-244∟.
doi: 10.1177/1941874419832443∟.
PMID: 31534618∟.
Case
report. ˍ
Sherif
RS, Elshemey WM, Attalla EM.
The
risk of secondary cancer in pediatric medulloblastoma patients due
to three-dimensional conformal radiotherapy and
intensity-modulated radiotherapy.
Indian
J Cancer. 2019 Feb 28, 2018;55(4):372-376∟.
doi: 10.4103/ijc.IJC_410_18∟.
PMID:
30829273∟.
Observational
study.
ˍ